-
UPDATE: Mereo BioPharma (MREO) Reports Positive Early 6 Month Data from Open Label Arm of Phase 2b Clinical Study of BPS-804 (setrusumab)
-
Mereo BioPharma Group plc Announces Positive Early 6 Month Data from the Open Label Arm of the Phase 2b Clinical Study in Adult Patients with Type I, III or IV Osteogenesis Imperfecta Treated with the
-
Mereo BioPharma Group plc (“Mereo” or the “Company” or the “Group”) Intention to Purchase Shares by Trustee of Employee Benefit Trust
-
Mereo Biopharma to Announce Preliminary Results for the Full Year 2018 and Host Conference Call on April 29, 2019
-
Mereo Biopharma to Announce Preliminary Results for the Full Year 2018 and Host Conference Call on April 29, 2019
-
Mereo BioPharma Group plc ("Mereo" or the "Company" or the "Group") Admission to trading on AIM of New Shares and initiation of trading on Nasdaq of American Depositary Shares
-
Mereo BioPharma Group plc ("Mereo" or the "Company" or the "Group") Admission to trading on AIM of New Shares and initiation of trading on Nasdaq of American Depositary S
-
Mereo Publicly Files Registration Statement on Form F-4 with U.S. Securities and Exchange Commission
-
Mereo BioPharma to Present at The BMO Prescriptions for Success Healthcare Conference on 12 December 2018
-
Proposed Combination of Mereo BioPharma and OncoMed Pharmaceuticals

